Willow Biosciences (CSE: WLLW) recently entered a joint development agreement (“JDA”) with leading cannabinoid manufacturer Noramco Inc. to develop a yeast-based biosynthesis platform for the production and distribution of cannabidiol (“CBD”) (http://cnw.fm/KZdi0). An article further discussing the company reads, “The JDA is mutually exclusive and creates an enviable arrangement designed to take advantage of each company’s … Continue reading “CannabisNewsBreaks – Willow Biosciences Inc. (CSE: WLLW) Joint Development Agreement to Create Biosynthesis Platform for CBD Production, Distribution”
Canada-based Willow Biosciences (CSE: WLLW) was recently featured in a video by InvestmentPitch Media detailing how the company utilizes its proprietary biosynthetic processes to deliver high yields of ultra-pure, low-cost cannabinoids. An article further discussing the company reads, “The video (http://cnw.fm/7MJm1) highlights a recent joint development agreement between Alberta, Canada-based Willow Biosciences and Delaware-headquartered Noramco … Continue reading “CannabisNewsBreaks – Willow Biosciences Inc. (CSE: WLLW) Employs Proprietary Biosynthetic Processes to Develop Ultra-Pure CBD”
A joint development agreement signed with Noramco Inc., the world’s largest producer of chemically synthesized cannabinoids and pharmaceutical APIs, is expected to scale the development of Willow’s CBD biosynthesis program The collective market for CBD sales in the U.S. is expected to exceed $20 billion by 2024, while the cannabinoid-based pharmaceuticals market may reach $50 … Continue reading “Willow Biosciences Inc. (CSE: WLLW) Developing Biosynthesis Platform for Production of Low-Cost, Pharmaceutical-Grade CBD”
Alberta, Canada-based Willow Biosciences (CSE: WLLW) is a leading developer of biosynthetic production systems for high-value, plant-derived active pharmaceutical ingredients (“APIs”) and intermediates. A recent article discussing Willow Biosciences reads, “The company’s expertise in the esoteric field of biosynthesis and in delivering commercial fermentation pathways for the production of pharmaceutical-grade compounds grew from its origins … Continue reading “CannabisNewsBreaks – Why Willow Biosciences Inc. (CSE: WLLW) Is ‘One to Watch’”
Canada-based Willow Biosciences and U.S.-based Noramco are teaming to biosynthetically produce and market pharmaceutical-grade cannabidiol (CBD) The companies expect to deliver yeast-cultivated CBD as a low-cost, ultra-pure alternative to cannabis cultivation that avoids large-scale plant waste from greenhouse processes Yeast-grown pharmaceutical ingredients have long served as fodder for insulin and other important drugs; the growing … Continue reading “Video Outlines Benefits of Willow Biosciences Inc.’s (CSE: WLLW) JDA to Develop CBD through Biosynthesis”
Exclusive joint development agreement with Noramco, the world’s largest producer of chemically synthesized cannabinoids and pharmaceutical APIs, to commercialize biosynthesized CBD Willow is fully funded with $37 million and expects to have more than $15 million on the balance sheet once the biosynthesized CBD isolate is ready to sell as a product Experienced research team … Continue reading “Willow Biosciences Inc. (CSE: WLLW) is “One to Watch””
Willow Biosciences Inc. (CSE: WLLW), a leading developer of biosynthetic production systems for plant-derived active pharmaceutical ingredients (APIs) and intermediates, in early June announced its entry into an exclusive joint development agreement with Noramco Inc., a leading manufacturer of cannabinoids. Per the update, the two firms intend to collaboratively develop a yeast-based biosynthesis platform for … Continue reading “CannabisNewsBreaks – Willow Biosciences Inc. (CSE: WLLW) Enters Joint Development Agreement with Noramco Inc.”
